D. E. Shaw & Co. Inc. Increases Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

D. E. Shaw & Co. Inc. increased its position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 9.8% in the 4th quarter, HoldingsChannel reports. The fund owned 1,239,459 shares of the company’s stock after purchasing an additional 110,882 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Zentalis Pharmaceuticals were worth $3,756,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Barclays PLC increased its holdings in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after acquiring an additional 11,748 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Zentalis Pharmaceuticals by 22.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 497,362 shares of the company’s stock valued at $1,507,000 after buying an additional 91,152 shares in the last quarter. Virtu Financial LLC purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $76,000. SG Americas Securities LLC grew its holdings in Zentalis Pharmaceuticals by 115.6% during the 4th quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock valued at $171,000 after buying an additional 30,240 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $68,000.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $1.26 on Monday. The company has a market cap of $90.66 million, a PE ratio of -0.51 and a beta of 1.81. The stock has a 50-day moving average price of $1.44 and a 200-day moving average price of $2.33. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $13.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.67). As a group, analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Scott Dunseth Myers acquired 21,000 shares of the stock in a transaction on Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the transaction, the director now owns 281,192 shares of the company’s stock, valued at $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ZNTL. Wells Fargo & Company reduced their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Wedbush reaffirmed a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. Finally, UBS Group reduced their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.